Use of defined TLR ligands as adjuvants within human vaccines.
about
Adjuvants: Classification, Modus Operandi, and LicensingThe Use of Synthetic Carriers in Malaria Vaccine DesignChoice and Design of Adjuvants for Parenteral and Mucosal VaccinesUse of lectin-functionalized particles for oral immunotherapyMechanisms of HIV protein degradation into epitopes: implications for vaccine designRole of innate immunity in neonatal infectionSalmonella as a vaccine delivery vehicleImmunization with L. sigmodontis microfilariae reduces peripheral microfilaraemia after challenge infection by inhibition of filarial embryogenesisTLR4 and NKT cell synergy in immunotherapy against visceral leishmaniasisRecent advances of vaccine adjuvants for infectious diseasesImmunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in miceImmune Adjuvant Effect of Molecularly-defined Toll-Like Receptor LigandsClinical vaccine development for H5N1 influenza.GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.Single-Dose CpG Immunization Protects Against a Heterosubtypic Challenge and Generates Antigen-Specific Memory T Cells.The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?Controlling the HIV/AIDS epidemic: current status and global challengesAdjuvant solution for pandemic influenza vaccine productionThe simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.Vaccine adjuvant informatics: from data integration and analysis to rational vaccine adjuvant design.TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Vaccines for Acinetobacter baumannii: thinking "out of the box".Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.Chemokines as Cancer Vaccine Adjuvants.Modulation of innate immune signaling by the secreted form of the West Nile virus NS1 glycoproteinCombination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.Classical Flt3L-dependent dendritic cells control immunity to protein vaccineSex Differences in monocytes and TLR4 associated immune responses; implications for systemic lupus erythematosus (SLE)Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery.Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs.The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.Synergistic induction of interferon α through TLR-3 and TLR-9 agonists identifies CD21 as interferon α receptor for the B cell responseCombined TLR7/8 and TLR9 ligands potentiate the activity of a Schistosoma japonicum DNA vaccine.The effect of different adjuvants on immune parameters and protection following vaccination of sheep with a larval-specific antigen of the gastrointestinal nematode, Haemonchus contortusFlagellin as carrier and adjuvant in cocaine vaccine development.Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains.MyD88 and TLR9 dependent immune responses mediate resistance to Leishmania guyanensis infections, irrespective of Leishmania RNA virus burdenIntralymphatic immunotherapy and vaccination in mice.
P2860
Q26747586-305C942C-D83C-4B7A-9837-EC29F4096A6CQ26777053-D4B8D947-CBF1-485F-A97F-2ECDA829E90CQ26783488-CC0D7D2D-2EA2-4D92-A16F-C8F650D4D1C9Q26849550-8379B542-98DC-4E51-88D7-4D32425ED603Q26866505-3EA1113F-8A4F-4998-B891-1B6138F083CEQ26999064-1E67D416-30D6-4B6C-87BE-4E64F5C0ED53Q27011946-3AAFCBCD-3D3F-4386-83E8-C8AD29339AEDQ27305577-70B39F8D-3187-434A-9CB2-E80076957C4CQ27346402-3AB1B366-FBA5-49AE-A758-8AB6FB0E2D49Q28083679-E8C62E6A-C907-4637-8B6C-F60E87BDB263Q28730052-5374F66F-6A77-4BD1-9913-70DFDDECA942Q28972540-0422C315-BF6F-450E-82FD-DEF9897FB41BQ30222083-5C08E8FE-AE57-4672-8CE5-C4C3347BB5C0Q30359243-70A9BB27-3A86-42C6-B02D-88D3EA8A8174Q30367140-B5FEC49F-996C-420F-BF0D-6A50FA25290BQ30376518-04B8111D-5DE0-4ABF-BE75-C5C4CAF7590DQ30406147-69E7A163-C996-4D01-AB6E-D524191E2856Q30420558-43538002-C4C0-42DE-A674-10D86E21575EQ30422038-770C8D98-41FF-4AD1-A32C-C5796BF0D259Q30528191-E78FD0AF-8688-45F5-BA35-63BD1996341AQ30759814-F39DC5B0-91C3-425E-A43E-11975761FA42Q30841163-05A565DF-AD5A-4BB8-9517-846877D87DD2Q31076192-DC500517-0FCA-450A-BCC6-EE743C53BD63Q33637895-BE9ACE67-5114-43E0-9902-32E7AF97CB1EQ33746872-F8248126-4AA4-4E83-8FAB-1A798CF170ABQ33792344-D40AF543-3848-4975-A354-8D47D189FDE1Q33821633-E331DB21-00A3-442F-AC72-5AAD568A59FAQ33853324-EAA9E8F3-C0C7-477E-BB16-6128C5D4892CQ34089167-2CA80CF8-79AB-42D9-81A5-B79EDC92B37FQ34323715-D4959CE8-344A-4F8A-91A7-0BAC41B0BFA0Q34455041-1551E4FD-79E4-48F2-9D2F-718AC0D1FAE3Q34514089-5873D167-0B58-4044-A41E-0F62B5CD4340Q34618662-05AACF09-2891-4836-A25E-3C3CAD002AB3Q34629175-79936DCE-070B-4111-B4BE-9AEE2C0543D8Q34675128-CC7FE4DE-230E-4462-A512-92C6C35FD65BQ35036362-F3109DA8-3B52-4FDA-981F-801E430CB171Q35057556-AAF7DAB2-0BE4-4BE7-8B3C-97F2DEAA97CAQ35088222-411D4857-7194-4503-8B66-852B8BEF45F7Q35163825-A96F5ECE-8181-409E-B2AA-6A946F00BE6FQ35389863-69D0CC50-9EFA-4161-8B1D-02E87870957D
P2860
Use of defined TLR ligands as adjuvants within human vaccines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of defined TLR ligands as adjuvants within human vaccines.
@en
Use of defined TLR ligands as adjuvants within human vaccines.
@nl
type
label
Use of defined TLR ligands as adjuvants within human vaccines.
@en
Use of defined TLR ligands as adjuvants within human vaccines.
@nl
prefLabel
Use of defined TLR ligands as adjuvants within human vaccines.
@en
Use of defined TLR ligands as adjuvants within human vaccines.
@nl
P2860
P50
P1476
Use of defined TLR ligands as adjuvants within human vaccines
@en
P2093
Hillarie Plessner Windish
P2860
P304
P356
10.1111/J.1600-065X.2010.00978.X
P577
2011-01-01T00:00:00Z